
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is well-positioned for long-term success with a promising drug in its pipeline, a well-structured development plan, and strong leadership. The potential for blockbuster sales in a large global market makes this stock an attractive investment opportunity. However, regulatory risks should be closely monitored as the drug targets unique receptors. With a solid financial foundation and experienced leadership, Minerva Neurosciences shows potential for significant growth and profitability in the future.
Bears say
Minerva Neurosciences is currently focused on the development and commercialization of proprietary product candidates to treat CNS diseases, with a primary focus on its leading product Roluperidone. However, challenges lie ahead as Minerva must execute a successful confirmatory Phase 3 trial for the treatment of negative symptoms in patients with schizophrenia. Despite promising results in previous trials, a high placebo response rate remains a key concern, and the company must continue to carefully manage this in order to achieve regulatory approval. Additionally, concerns remain around the company's financials, with negligible product sales and reliance on external funding sources, such as the recent private placement and shelf offering, to continue operations.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares